Screener
Relay Therapeutics, Inc. RLAY Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338056
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from issuance of common stock through follow-on offering, net | 296,814 | — |
| Proceeds from issuance of common stock through exercise of stock options | 5,583 | — |
| Proceeds from issuance of common stock via employee stock purchase plan | 901 | 653 |
| Net cash provided by financing activities | 462,517 | 653 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 37,171 | (10,207) |
| Cash, cash equivalents, and restricted cash at beginning of period | 85,354 | 126,406 |
| Cash, cash equivalents, and restricted cash at end of period | $122,525 | $116,199 |
| Supplemental disclosure of non-cash activities: |
Item 1. Financial Statements.
FAQ
- What is Relay Therapeutics, Inc.'s financing cash flow?
- Relay Therapeutics, Inc. (RLAY) reported financing cash flow of $323.74M in Q2 2026.
- What is the long-term trend for Relay Therapeutics, Inc.'s financing cash flow?
- Over 3 years (2021 to 2024), Relay Therapeutics, Inc.'s financing cash flow has grown at a -11.4% compound annual growth rate (CAGR), from $388.09M to $270.15M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Relay Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude